European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Soraprazan - a new regenerative therapy for Stargardt's disease

Obiettivo

Soraprazan – a new regenerative therapy for Stargardt’s disease
Abnormal accumulation of lipofuscin in the RPE cells is a hallmark in Stargardt's disease. As lipofuscin cannot be removed from the RPE cells in the eyes neither spontaneously nor with existing therapies, the accumulation of lipofuscin in the RPE cells of the eyes results in the degradation of the RPE cells and consequently in worsening of visual acuity and could lead to blindness. Soraprazan was able to show removal of lipofuscin in RPE cells. Aim of the phase II trial in this project is to evaluate savety and efficacy or orally taken Soraprazan treatment compared to placebo.

Invito a presentare proposte

H2020-SC1-2016-2017

Vedi altri progetti per questo bando

Bando secondario

H2020-SC1-2017-Single-Stage-RTD

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Contribution nette de l'UE
€ 467 500,00
Indirizzo
GESCHWISTER-SCHOLL-PLATZ
72074 Tuebingen
Germania

Mostra sulla mappa

Regione
Baden-Württemberg Tübingen Tübingen, Landkreis
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 467 500,00

Partecipanti (11)